Market revenue in 2023 | USD 132.8 million |
Market revenue in 2030 | USD 133.8 million |
Growth rate | 0.1% (CAGR from 2023 to 2030) |
Largest segment | Immunoturbidimetric assay |
Fastest growing segment | Immunoturbidimetric Assay |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Immunoturbidimetric Assay, Chemiluminescence Immunoassay, Other Assay Types, ELISA |
Key market players worldwide | Thermo Fisher Scientific Inc, Roche Holding AG ADR, Danaher Corp, Quest Diagnostics Inc, Siemens Healthineers AG ADR, Abbott Laboratories, Merck KGaA, Zoetis Inc Class A, QuidelOrtho Corp, Horiba Ltd, Getein Biotech, Boditech Med, Randox, Aidian |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to c-reactive protein testing market will help companies and investors design strategic landscapes.
Immunoturbidimetric assay was the largest segment with a revenue share of 48.49% in 2023. Horizon Databook has segmented the Brazil c-reactive protein testing market based on immunoturbidimetric assay, chemiluminescence immunoassay, other assay types, elisa covering the revenue growth of each sub-segment from 2018 to 2030.
Brazil is the largest market in the Latin American region and is supported by favorable government policies for diagnostic testing and is expected to grow at a good rate over the forecast period. Other factors like presence of bigger and multinational players or their distributors in the country, improving infrastructure, and expansion of advanced pathological labs to rural areas are expected to propel the market growth.
Moreover, rise in prevalence of inflammatory disorders in Brazil is expected to increase penetration of CRP testing in the country. Non-communicable diseases have become a major health priority in Brazil. These diseases accounted for over 74% of all deaths in 2019.
According to WHO, approximately 1,320,000 deaths due to noncommunicable diseases occurred in Brazil in 2019. Recently, there has been decline in the incidence of cardiovascular & chronic respiratory diseases, owing to successful implementation of various health policies that have led to increase in access to primary healthcare and decrease in the number of smokers.
Horizon Databook provides a detailed overview of country-level data and insights on the Brazil c-reactive protein testing market , including forecasts for subscribers. This country databook contains high-level insights into Brazil c-reactive protein testing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account